https://www.fortunebusinessinsights.com/industry-reports/connected-drug-delivery-devices-market-100380
https://www.fortunebusinessinsights.com/industry-reports/connected-drug-delivery-devices-market-100380
https://www.fortunebusinessinsights.com/industry-reports/connected-drug-delivery-devices-market-100380
https://www.bd.com/en-us/offerings/capabilities/hazardous-drug-safety/texium-system/texium-bonded-syringe
The global connected drug delivery devices market was valued at USD 361.1 million in 2018 and
is anticipated to reach approximately USD 25,810.9 million by 2032, growing at a robust
CAGR of 35.7% during the forecast period from 2018 to 2032. In 2018, North America led
the market, accounting for a dominant share of 70.06%.
The global connected drug delivery devices market has experienced significant growth in recent years
and is expected to expand rapidly over the forecast period. This growth is driven by increasing demand
for smart healthcare solutions that enhance patient adherence, enable real-time monitoring, and
improve treatment outcomes. The integration of digital technologies such as IoT, mobile health
applications, and cloud-based platforms is transforming drug delivery practices. Regions like North
America have been at the forefront of adoption due to advanced healthcare infrastructure and favorable
regulatory frameworks. As awareness and access to connected therapeutics continue to rise globally, the
market is poised for substantial expansion in the coming years.
Continue reading for more details:
https://www.fortunebusinessinsights.com/industry-reports/connected-drug-delivery-devices-market-
100380
Market Segmentation
• By Product Type: The market is segmented into injectable connected drug delivery devices,
inhalation-based devices, and wearable systems.
• By Technology: Segmentation includes Bluetooth-enabled, NFC-based, and other wireless
technology-based connected drug delivery devices.
• By Application: Includes diabetes management, respiratory diseases, cardiovascular treatments, and
oncology, with diabetes and asthma treatment driving major demand.
• By End User: The market serves homecare settings, hospitals, and specialty clinics, with homecare
emerging as a key growth area for connected drug delivery devices.
• By Drug Type: Biologics, insulin, and other high-value therapeutics are often paired with connected
drug delivery devices for enhanced patient compliance.
List Of Key Companies Profiled:
• Proteus Digital Health
• Ypsomed Holding
• F. Hoffmann-La Roche Ltd
• BD
• West Pharmaceutical Services
• Propeller Health (A ResMed Company)
• Adherium
• Cohero Health, Inc.
Market Growth
• The connected drug delivery devices market is witnessing strong growth due to increasing demand
for patient-centric and personalized medication management.
• Advancements in digital health technologies and integration of IoT and AI are propelling the
adoption of connected drug delivery devices.
• Rising prevalence of chronic conditions such as diabetes, asthma, and cardiovascular diseases is
significantly contributing to the expansion of the connected drug delivery devices market.
•
Increased awareness of treatment adherence and patient engagement is pushing healthcare
providers and pharmaceutical companies to invest in connected drug delivery devices.
• The post-pandemic shift toward remote care and self-administration has further accelerated the
growth of connected drug delivery devices.
Restraining Factors
• High costs associated with the development and deployment of connected drug delivery devices
may limit accessibility in lower-income markets.
• Concerns about data privacy, cybersecurity, and patient confidentiality pose challenges to the
widespread adoption of connected drug delivery devices.
• Regulatory complexities and time-consuming approval processes slow the pace of innovation and
commercialization of new connected drug delivery devices.
•
Limited interoperability between healthcare systems and connected drug delivery devices may
restrict smooth integration into existing infrastructure.
• Patient resistance to adopting technology-based healthcare solutions, especially among the elderly,
may also act as a barrier to connected drug delivery devices adoption.
Regional Analysis
• North America leads the connected drug delivery devices market due to advanced healthcare
infrastructure, strong digital health adoption, and favorable reimbursement policies.
• Europe follows closely with increasing demand for home-based care solutions and government
support for digital therapeutics and connected drug delivery devices.
• Asia-Pacific is the fastest-growing region, driven by increasing healthcare access, a rising elderly
population, and growing chronic disease burden fueling demand for connected drug delivery
devices.
• Latin America and Middle East & Africa are gradually adopting connected drug delivery devices,
supported by improving healthcare systems and rising interest in digital health technologies.